Literature DB >> 11356984

The role of corticotropin-releasing factor in drug addiction.

Z Sarnyai1, Y Shaham, S C Heinrichs.   

Abstract

The goal of this article is to summarize available data examining the physiological significance of brain corticotropin-releasing factor (CRF) systems in mediating the behavioral and physiological effects of several classes of abused drugs, including opioid and psychostimulant drugs, alcohol and sedative hypnotics, nicotine, and cannabinoids. An initial discussion of CRF neurobiology is followed by consideration of the role of CRF in drug-induced activation of the hypothalamic-pituitary-adrenocortical (HPA) axis, the behavioral effects of drugs (e.g., locomotor activity, anxiogenic-like responses), drug self-administration, drug withdrawal, and relapse to drug-seeking. Subsequently, neurochemical changes in brain CRF in response to acute and chronic drug exposure are examined. A major conclusion derived from the data reviewed is that extrahypothalamic brain CRF systems are critically involved in behavioral and physiological manifestations of drug withdrawal and in relapse to drug-taking behavior induced by environmental stressors. On the other hand, it appears that hypothalamic CRF, via its action on the HPA axis, is involved in the reinforcing effects of cocaine and alcohol, and the locomotor activating effects of psychostimulant drugs. These preclinical data may provide a rationale for the development of CRF-based pharmacotherapies for the treatment of compulsive drug use in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356984

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  151 in total

Review 1.  Neural systems underlying opiate addiction.

Authors:  Taco J De Vries; Toni S Shippenberg
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 2.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

3.  Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Keely M Murphy; Liping Meng; Janitza Montalvo-Ortiz; Ziling Zeng; Benedict J Kolber; Shanshan Zhang; Louis J Muglia; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Effects of a Rhodiola rosea L. extract on the acquisition, expression, extinction, and reinstatement of morphine-induced conditioned place preference in mice.

Authors:  Laura Mattioli; Federica Titomanlio; Marina Perfumi
Journal:  Psychopharmacology (Berl)       Date:  2012-03-16       Impact factor: 4.530

Review 5.  [Oxytocin and the mechanisms of alcohol dependence].

Authors:  Till Faehrmann; Gerald Zernig; Sergei Mechtcheriakov
Journal:  Neuropsychiatr       Date:  2017-06-21

6.  Escalated cocaine "binges" in rats: enduring effects of social defeat stress or intra-VTA CRF.

Authors:  Michael Z Leonard; Joseph F DeBold; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2017-07-18       Impact factor: 4.530

7.  The effects of medial prefrontal cortex infusions of cocaine in a runway model of drug self-administration: evidence of reinforcing but not anxiogenic actions.

Authors:  Daniel Guzman; Justin M Moscarello; Aaron Ettenberg
Journal:  Eur J Pharmacol       Date:  2009-01-10       Impact factor: 4.432

Review 8.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

Review 9.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 10.  Stress is a principal factor that promotes tobacco use in females.

Authors:  Oscar V Torres; Laura E O'Dell
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-04-22       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.